JFG
SLNO

Jefferies Financial Group’s Soleno Therapeutics SLNO Stock Holding History

Jefferies Financial Group’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-119,200
Closed -$5.52M – 2164
2025
Q4 		$5.52M Buy
+119,200
New +$6.54M 0.03% 466

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Jefferies Financial Group's SLNO Position: Q1 2026 in Review

Jefferies Financial Group sold out of Soleno Therapeutics (SLNO) in Q1 2026, closing a stake of 29,304 shares — an estimated $1.36M sold.

Jefferies Financial Group first reported a position in SLNO in Q4 2023 and held it in 9 quarters. The position peaked at $1.78M in Q3 2024. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Jefferies Financial Group reported no remaining Soleno Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jefferies Financial Group sold 29,304 Soleno Therapeutics shares in Q1 2026, an estimated $1.36M.
  • Jefferies Financial Group first reported a position in Soleno Therapeutics in Q4 2023 and held it in 9 quarters.
  • Jefferies Financial Group's Soleno Therapeutics position peaked at $1.78M in Q3 2024.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.